A team of researchers has developed a new assessment to predict whether surgeons are ready to use the da Vinci robot for surgery, according to a Market Watch report.
The new technology, called MScore, provides a more precise analysis of actual surgical performance. Mimic Technologies, the simulation company that built the da Vinci simulation program, is developing MScore by using performance data collected from more than 100 surgeons and academics that have completed at least 75 separate cases.
MScore compares a novice surgeon performance to an experienced surgeon performance in order to objectively assess a surgeon's skills. The evaluation can help hospitals decide whether a surgeon is ready to use the da Vinci system to operate on patients. The MScore system also encourages continued training long after proficiency has been established by monitoring performance over time.
Related Articles on Surgical Supplies:
FDA, Life Sciences Trade Group Partner to Improve Medical Device Review
Covidien Elects President and CEO Jose E. Almeida Chairman of the Board
Investment in Medical Device and Biotech Firms Hit 15 Year Low in 2011
The new technology, called MScore, provides a more precise analysis of actual surgical performance. Mimic Technologies, the simulation company that built the da Vinci simulation program, is developing MScore by using performance data collected from more than 100 surgeons and academics that have completed at least 75 separate cases.
MScore compares a novice surgeon performance to an experienced surgeon performance in order to objectively assess a surgeon's skills. The evaluation can help hospitals decide whether a surgeon is ready to use the da Vinci system to operate on patients. The MScore system also encourages continued training long after proficiency has been established by monitoring performance over time.
Related Articles on Surgical Supplies:
FDA, Life Sciences Trade Group Partner to Improve Medical Device Review
Covidien Elects President and CEO Jose E. Almeida Chairman of the Board
Investment in Medical Device and Biotech Firms Hit 15 Year Low in 2011